Marilyn Tavenner, the face of private insurers, does not think Affordable Care Act exchanges are about to implode. But she does think Congress will have to make some tough decisions relatively soon about how much to buffer insurers from risk.
Health insurers do not want congressional Republicans to block potential settlements of their lawsuits against the administration involving Obamacare, according to Marilyn Tavenner, president and CEO of America’s Health Insurance Plans.
Total Medicaid spending and enrollment slowed in 2016 after record increases in 2015, according to a new Kaiser Family Foundation report.
Senate Democrats signaled they will continue to push for additional opioid funding in the lame duck, releasing a report Wednesday highlighting the need for it.
After Donald Trump brought up MIT economist Jonathan Gruber in Sunday night’s debate, Gruber struck back, calling Trump’s health policy plans “garbage salad.” Gruber helped write the Affordable Care Act, which Trump railed against during the debate.
Mylan Pharmaceuticals increased government charges for EpiPens by 453 percent between 2011 and 2015, not counting rebates, according to an analysis by the office of Sen. Chuck Grassley (R-Iowa). EpiPen unit sales increased only 51 percent over the same time period.
It’s common wisdom that the future of Obamacare depends on who occupies the White House come January 2017. But what remains unclear is whether Congress will be able to pass any form of health legislation under either a President Hillary Clinton or a President Donald Trump.
The Centers for Medicare and Medicaid Services and private insurers do not have a clear set of standards when it comes to anti-opioid abuse efforts, and available resources are unused, according to a new report by the Senate Permanent Subcommittee on Investigations.
As Hillary Clinton, President Obama, and most Senate Democrats coalesce around a government-run insurance agency as part of the solution to Obamacare cost woes, a large problem remains unaddressed: Insurers hate the public option.
President Obama signed into law Friday an extension of a program designed to incentivize drug makers to find treatments to rare pediatric diseases. It was set to expire at the end of the month, but will now last until the end of the year.
Information never stops. We help you start your day by making sense of it all. Over 150,000 government and industry executives rely on Morning Consult to stay informed. Our original reporting and morning email briefings make it possible for you to know everything you need to know, every day, at the intersection of Wall Street and business strategy, policy and politics.
